Öz
Aim: The aim of this study is to compare the demographic, clinical, laboratory characteristics and mortality rates of
malignant patients followed in the COVID-19 and non-COVID-19 intensive care units (ICU) during the pandemic.
Material and Methods: This is a retrospective observational study that included patients with oncological diagnosis of
COVID-19 and non-COVID-19 hospitalized in the ICU between March 23, 2020 - January 31, 2022. Adult patients (≥18
years), with hematological or solid organ malignancy were included in this study. Patients were divided into two groups;
first group admitted to ICU with the diagnosis of COVID-19 (polymerase chain reaction (PCR) test positive) and second
gropu admitted to ICU without the diagnosis of COVID-19 (PCR test negative and clinically and radiologically confirmed
that they were not COVID-19). Data of two groups were compared.
Results: A total of 283 patients, 150 of whom had malignancies with COVID-19, and 133 patients with malignancies with
non-COVID-19 were included in the study. When the malignancy characteristics of the two groups were compared; cured
malignancy was significantly higher in the COVID-19 group. The rates of patients with solid organ malignancies were
statistically higher in the COVID-19 group (85.3%), while those with hematological malignancies (24.1%) were statistically
higher in the non-COVID-19 group (p=0.04 and 0.03, respectively). In addition, lung carcinoma (22%) was statistically
significantly higher in the COVID-19 group. Predictors of mortality were invasive mechanical ventilator (IMV) requirement,
duration of IMV, concomitant neurologic disease and need of vasopressor/inotrope.
Conclusion: It was concluded that the mortality rate in COVID-19 malignant patients was lower than that of non-COVID-19
malignant patients, and that requirement and duration of IMV, the need of vasopessor/inotrope, and concomitant
neurological disease were effective in mortality in all malignant patients. We think that the higher mortality in the nonCOVID-19 patient group may be due to factors such as end stage of the malignancy, clinical course, and immunosuppressive
treatment (radiotherapy, chemotherapy, etc.).
Anahtar Kelimeler
COVID-19 non-COVID-19 malignancy oncological patients mortality mortality predictors
Kaynakça
- 1. Fu C, Stoeckle JH, Masri L et al. COVID-19 Outcomes in Hospitalized Patients With Active Cancer: Experiences From a Major New York City Health Care System. Cancer 2021; 7: 10.
- 2. Yang K, Sheng Y, Huang C et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 904–13
- 3. Sawyers A, Chou M, Johannet P et al. Clinical outcomes in cancer patients with COVID-19. Cancer Reports 2021; 4: 1413.
- 4. Zhang H, Han H, He T et al. Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis. JNCI J Natl Cancer Inst 2021; 113: 371-80.
- 5. Aboueshia M, Hussein MH, Attia AS et al. Cancer and COVID-19: analysis of patient Outcomes. Future Oncol. 10.2217/fon-2021-0121.
- 6. Lee LYW, Cazier JB, Starkey T et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020; 21: 1309–16.
- 7. Díaz-Díaz D, Martínez MV, Herrejón EP et al. Oncological patients admitted to an intensive care unit. Analysis of predictors of inhospital mortality. Med Intensiva 2018; 42: 346-53.
- 8. De Jong A, Jung B, Jaber S. Intubation in the ICU: we could improve our practice. Critical Care 2014; 18: 209
- 9. Reyes LF, Rodriguez A, Bastidas A et al. Dexamethasone as riskfactor for ICU-acquired respiratory tract infections in severe COVID-19. Journal of Critical Care 2022; 69: 154014.
- 10. Sanyaolu A, Okorie C, Marinkovic A et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med 2020; 2: 1069–76.
- 11. Nadkarni AR, Vijayakumaran SC, Gupta S, Divatia JV. Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and MetaAnalysis. JCO Global Oncol 2021; 7: 1286-305.
- 12. Plais H, Labruyère M, Creutin T et al. Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study. Front. Oncol. 2022; 12: 858276.
- 13. Shoumariyeh K, Biavasco F, Ihorst G et al. Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Medicine 2020; 9: 8412–22
- 14. Tavakolpour S, Rakhshandehroo T. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol Lett 2020; 225: 31–2.
- 15. Lee J, Park SS, Kim TY, et al. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers (Basel) 2021; 13: 471.
- 16. Ahnach M, Zbiri S, Nejjari S et al. C-reactive protein as an early predictor of COVID-19 severity. J Med Biochem 2020; 39: 500-7.
- 17. Xu Y, Yang H, Wang J et al. Serum Albumin Levels are a Predictor of COVID-19 Patient Prognosis: Evidence from a Single Cohort in Chongqing, China. International Journal of General Medicine 2021; 14: 2785–97.
- 18. Turcato G, Zaboli A, Kostic I, et al. Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study. Emerg Med J 2022; 39:63–9.
Öz
Amaç: Bu çalışmanın amacı, pandemi süresince COVID-19 ve non-COVID-19 yoğun bakım ünitelerinde (YBÜ) takip edilen
malign hastaların demografik, klinik, laboratuvar özelliklerini ve mortalite oranlarını karşılaştırmaktır.
Gereç ve Yöntemler: Bu çalışma 23 Mart 2020- 31 Ocak 2022 tarihleri arasında COVID-19 ve non-COVID-19 YBÜ’de yatan
onkolojik tanılı hastaların dahil edildiği retrospektif gözlemsel çalışmadır. Erişkin (≥18 yaş), hematolojik ya da solid organ
malignitesi olan hastalar çalışmaya alındı. Hastalar iki gruba ayrıldı: Birinci grup COVID-19 tanısı (Polimerase chain reaction
(PCR) testi pozitif) ile COVID-19 YBÜ’ne kabul edilen, ikinci grup ise COVID-19 tanısı dışlanarak (PCR testi negatif ve klinik
ve radyolojik olarak COVID-19 olmadığı doğrulanan) non-COVID-19 YBÜ’ne kabul edilen hastalar oluşturdu. İki grubun
verileri karşılaştırıldı.
Bulgular: Çalışmaya 150 COVID-19 ve malignitesi olan, 133 non-COVID-19 ve malignitesi olan toplam 283 hasta dahil
edildi. İki grubun malignite özellikleri karşılaştırıldığında; COVID-19 grubunda malignitede kür sağlananlar anlamlı olarak
fazlaydı. Solid organ malignitesi olanların oranları COVID-19 grubunda (%85,3), hematolojik malignitesi olanların oranı
(%24,1) ise non-COVID-19 grubunda istatistiksel farkla daha fazlaydı (sırasıyla, p=0.04 ve 0.03). Ayrıca akciğer karsinomu
(%22) COVID-19 grubunda istatistiksel olarak anlamlı olarak fazla idi. Tüm malign hastalarda mortalite prediktörü olarak;
invaziv mekanik ventilatör (IMV) ihtiyacı, IMV kalış süresinde artış, nörolojik hastalığın eşlik etmesi ve vazopressör/inotrop
ihtiyacı olarak belirlendi.
Sonuç: COVID-19 malign hastalarda mortalite oranının non-COVID-19 malign hastalardan daha düşük olduğu, tüm malign
hastalarda mortaliteye IMV gereksinimi ve süresi, vazopessör/inotrop ihtiyacı ve nörolojik hastalığın eşlik etmesinin etkili
olduğu sonucuna varıldı. Mortalitenin non-COVID-19 hasta grubunda daha fazla olmasını malignitenin ileri evresi, klinik
seyri, uygulanan immunsuprese tedavi (radyoterapi, kemoterapi gibi) gibi faktörlere bağlı olabileceğini düşünüyoruz.
Anahtar Kelimeler
COVID-19 nonCOVID-19 malignite onkolojik hastalar mortalite mortalite prediktörleri
Kaynakça
- 1. Fu C, Stoeckle JH, Masri L et al. COVID-19 Outcomes in Hospitalized Patients With Active Cancer: Experiences From a Major New York City Health Care System. Cancer 2021; 7: 10.
- 2. Yang K, Sheng Y, Huang C et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 904–13
- 3. Sawyers A, Chou M, Johannet P et al. Clinical outcomes in cancer patients with COVID-19. Cancer Reports 2021; 4: 1413.
- 4. Zhang H, Han H, He T et al. Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis. JNCI J Natl Cancer Inst 2021; 113: 371-80.
- 5. Aboueshia M, Hussein MH, Attia AS et al. Cancer and COVID-19: analysis of patient Outcomes. Future Oncol. 10.2217/fon-2021-0121.
- 6. Lee LYW, Cazier JB, Starkey T et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol 2020; 21: 1309–16.
- 7. Díaz-Díaz D, Martínez MV, Herrejón EP et al. Oncological patients admitted to an intensive care unit. Analysis of predictors of inhospital mortality. Med Intensiva 2018; 42: 346-53.
- 8. De Jong A, Jung B, Jaber S. Intubation in the ICU: we could improve our practice. Critical Care 2014; 18: 209
- 9. Reyes LF, Rodriguez A, Bastidas A et al. Dexamethasone as riskfactor for ICU-acquired respiratory tract infections in severe COVID-19. Journal of Critical Care 2022; 69: 154014.
- 10. Sanyaolu A, Okorie C, Marinkovic A et al. Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med 2020; 2: 1069–76.
- 11. Nadkarni AR, Vijayakumaran SC, Gupta S, Divatia JV. Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and MetaAnalysis. JCO Global Oncol 2021; 7: 1286-305.
- 12. Plais H, Labruyère M, Creutin T et al. Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study. Front. Oncol. 2022; 12: 858276.
- 13. Shoumariyeh K, Biavasco F, Ihorst G et al. Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. Cancer Medicine 2020; 9: 8412–22
- 14. Tavakolpour S, Rakhshandehroo T. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol Lett 2020; 225: 31–2.
- 15. Lee J, Park SS, Kim TY, et al. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers (Basel) 2021; 13: 471.
- 16. Ahnach M, Zbiri S, Nejjari S et al. C-reactive protein as an early predictor of COVID-19 severity. J Med Biochem 2020; 39: 500-7.
- 17. Xu Y, Yang H, Wang J et al. Serum Albumin Levels are a Predictor of COVID-19 Patient Prognosis: Evidence from a Single Cohort in Chongqing, China. International Journal of General Medicine 2021; 14: 2785–97.
- 18. Turcato G, Zaboli A, Kostic I, et al. Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study. Emerg Med J 2022; 39:63–9.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Özgün Makale |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Haziran 2022 |
| Yayımlandığı Sayı | Yıl 2022 Cilt: 13 Sayı: 2 |
Kaynak Göster
e-ISSN: 2149-8296
The content of this site is intended for health care professionals. All the published articles are distributed under the terms of
Creative Commons Attribution Licence,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.